309
Participants
Start Date
December 13, 2012
Primary Completion Date
December 31, 2015
Study Completion Date
December 31, 2015
CPX-351
First induction: 100 units/m2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m2 by 90-minute IV infusion on Days 1 and 3.
7+3 (cytarabine and daunorubicin)
"First induction: 7+3 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1, 2, and 3.~Second induction: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2.~Consolidation therapy: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2."
Columbia University, New York
Cornell U, Weill Medical College, New York
Montefiore Medical Center, The Bronx
New York Medical College, Valhalla
UPMC, Pittsburgh
Fox Chase Cancer Center, Philadelphia
Wake Forest University Health Services, Winston-Salem
Duke University Medical Center, Durham
Medical University of South Carolina, Charleston
Northside Hospital, Atlanta
University of Florida, Gainesville
H. Lee Moffitt Cancer Center, Tampa
University of Alabama at Birmingham, Birmingham
Sarah Cannon Research Institute, Nashville
Vanderbilt University, Nashville
Franciscan St. Francis Health, Indianapolis
University of Michigan, Ann Arbor
Medical College of Wisconsin, Milwaukee
University of Minnesota, Minneapolis
Northwestern University, Chicago
Rush University Medical Center, Chicago
University of Chicago, Chicago
Washington University, St Louis
University of Missouri, Columbia
University of Kansas Medical Center, Kansas City
Baylor Research Insitute, Dallas
UCLA, Los Angeles
Stanford University, Stanford
Providence Portland Medical Center, Portland
Oregon Health and Science University, Portland
Fred Hutchinson Cancer Research Center, Seattle
M.D. Anderson Cancer Center, Houston
University of CA San Diego, San Diego
Yale University, New Haven
Dana-Farber Cancer Institute, Boston
Dartmouth Hitchcock Medical Center, Lebanon
Hackensack University Medical Center, Hackensack
North Shore LIJ Health System, Long Island City
Hopital Maisonneuve-Rosemont, Montreal
University of North Carolina at Chapel Hill, Chapel Hill
University of Alberta Hospital, Edmonton
British Columbia Cancer Center, Vancouver
Princess Margaret Hospital, Toronto
Lead Sponsor
The Leukemia and Lymphoma Society
OTHER
Jazz Pharmaceuticals
INDUSTRY